Form 4: Kiromic Biopharma Director Michael Nagel Receives Restricted Stock Award

Director Michael Nagel of Kiromic Biopharma, Inc. reports the acquisition of 18,000 shares of restricted stock.

Summary

• Michael Nagel, a director at Kiromic Biopharma, Inc., filed a Form 4 to report changes in beneficial ownership.
• On March 18, 2024, Nagel acquired 18,000 shares of restricted stock.
• Following the transaction, Nagel directly owns 42,296 shares of Kiromic Biopharma, Inc.
• The restricted stock award vests on the one-year anniversary of the grant date.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The sentiment is neither positive nor negative.

Positives

• The acquisition of restricted stock by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders may view the director's acquisition of restricted stock as a positive sign of alignment with their interests.

Key Dates

Keywords

Form 4, Kiromic Biopharma, Restricted Stock, Beneficial Ownership, Director, Nagel, KRBP